Summary: Epigenetic targets are exciting new avenues for cancer drug discovery. Zhang and colleagues have designed the open-source EZH2 inhibitor JQEZ5 and shown antitumor efficacy in vitro and in vivo in preclinical studies in murine and human lung adenocarcinoma models expressing high levels of EZH2. Cancer Discov; 6(9); 949–52. ©2016 AACR.
See related article by Zhang and colleagues, p. 1006.
- ©2016 American Association for Cancer Research.